# NCT06396065 (NCT06396065)

> Phase III Study of AK112 for NSCLC Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06396065
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Summit Therapeutics
- Conditions: Non-Squamous Non-small Cell Lung Cancer
- Interventions: AK112 Injection; Placebo Injection
- Enrollment: 420
- Primary outcome: Progression-free survival (PFS)
- Primary outcome: Overall Survival (OS) in the ITT population

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 99
- YouTube: 11
- Podcasts: 11
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct06396065

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06396065", "email": "<work email>"}; the inbox owner confirms by the emailed link.